Published in J Natl Cancer Inst on August 04, 1999
Predictors of sun protection behaviors and severe sunburn in an international online study. Cancer Epidemiol Biomarkers Prev (2010) 1.21
Sunscreens, skin photobiology, and skin cancer: the need for UVA protection and evaluation of efficacy. Environ Health Perspect (2000) 1.15
UV-induced skin cancer at workplace and evidence-based prevention. Int Arch Occup Environ Health (2010) 1.05
Preventing excess sun exposure: it is time for a national policy. J Natl Cancer Inst (1999) 0.97
Sunscreen use and intentional exposure to ultraviolet A and B radiation: a double blind randomized trial using personal dosimeters. Br J Cancer (2000) 0.92
Correlates of sunburn experiences among U.S. adults: results of the 2000 National Health Interview Survey. Public Health Rep (2003) 0.92
Sunscreens in melanoma and skin cancer prevention. CMAJ (2005) 0.91
Childhood exposure to ultraviolet radiation and harmful skin effects: epidemiological evidence. Prog Biophys Mol Biol (2011) 0.88
Skin cancer prevention practices among malignant melanoma survivors: a systematic review. J Cancer Res Clin Oncol (2015) 0.85
Sun protection and sunbathing practices among at-risk family members of patients with melanoma. BMC Public Health (2011) 0.84
Tanning behavior among young frequent tanners is related to attitudes and not lack of knowledge about the dangers. Health Educ J (2009) 0.84
Sun-protective behaviors in populations at high risk for skin cancer. Psychol Res Behav Manag (2013) 0.83
More about: Sunscreen use and duration of sun exposure: a double-blind, randomized trial. J Natl Cancer Inst (2000) 0.82
Assessment of elementary school students' sun protection behaviors. Pediatr Dermatol (2009) 0.81
Squamous cell carcinoma of the skin (non-metastatic). BMJ Clin Evid (2010) 0.79
Suppression of PTEN transcription by UVA. J Biochem Mol Toxicol (2012) 0.78
A cluster randomized trial of sun protection at elementary schools. Results from year 2. Am J Prev Med (2011) 0.77
Detrimental effects of UV-B radiation in a xeroderma pigmentosum-variant cell line. Environ Mol Mutagen (2014) 0.77
Development and Characterization of a Novel in vitro Progression Model for UVB-Induced Skin Carcinogenesis. Sci Rep (2015) 0.77
Re: Sunscreen use and duration of sun exposure: a double-blind, randomized trial. J Natl Cancer Inst (1999) 0.76
Do high factor sunscreens offer protection from melanoma? West J Med (2000) 0.75
Identifying risk factors using a skin cancer screening program. Cancer Control (2013) 0.75
Has the sun protection factor had its day? Information on sunscreens should warn against excessive sun exposure. BMJ (2000) 0.75
Is there truly no benefit with sunscreen use and Basal cell carcinoma? A critical review of the literature and the application of new sunscreen labeling rules to real-world sunscreen practices. J Skin Cancer (2012) 0.75
Malignant melanoma (non-metastatic). BMJ Clin Evid (2007) 0.75
Prevalence of photoprotection and its associated factors in risk group for skin cancer in Teresina, Piauí. An Bras Dermatol (2017) 0.75
Utility of sun-reactive skin typing and melanin index for discerning vitamin D deficiency. Pediatr Res (2017) 0.75
Sunscreen use, wearing clothes, and number of nevi in 6- to 7-year-old European children. European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Natl Cancer Inst (1998) 3.49
Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer (1999) 3.19
Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med (1998) 3.04
High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med (1999) 2.98
Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol (1998) 2.68
Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol (1996) 2.61
Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med (1998) 2.42
High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol (1992) 2.12
Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol (2010) 2.06
A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br J Cancer (2010) 1.87
Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer (1995) 1.81
Response rate accuracy in oncology trials: reasons for interobserver variability. Groupe Français d'Immunothérapie of the Fédération Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol (1997) 1.77
Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int J Cancer (1997) 1.70
Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J Exp Med (1999) 1.67
Optimizing the outcome of surgery in patients with rectal cancer and synchronous liver metastases. Br J Surg (2010) 1.65
Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs. J Am Coll Surg (1996) 1.54
Advanced breast cancer incidence following population-based mammographic screening. Ann Oncol (2011) 1.53
Quantitation of antigen-reactive T cells in peripheral blood by IFNgamma-ELISPOT assay and chromium-release assay: a four-centre comparative trial. J Immunol Methods (2000) 1.53
Tumor necrosis factor-alpha augments tumor effects in isolated hepatic perfusion with melphalan in a rat sarcoma model. J Immunother (2000) 1.52
Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res (2000) 1.47
Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol (1998) 1.46
Adjuvant interferon-alpha for melanoma revisited: news from old and new studies. Ann Oncol (2001) 1.43
Coley's vaccine and TNF therapy. Nature (1992) 1.40
Anesthesiologists' management of isolated limb perfusion with "high-dose" tumor necrosis factor alpha. Anesthesiology (1993) 1.39
Interleukin-2-induced thyroid dysfunction is correlated with treatment duration but not with tumor response. J Clin Oncol (1993) 1.39
[Thyroid metastases as cause of thyroid swelling]. Ned Tijdschr Geneeskd (1993) 1.38
The AJCC staging proposal for cutaneous melanoma: comments by the EORTC Melanoma Group. Ann Oncol (2001) 1.38
Tetramer-guided analysis of TCR beta-chain usage reveals a large repertoire of melan-A-specific CD8+ T cells in melanoma patients. J Immunol (2000) 1.31
Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity. Cancer Res (2001) 1.31
Risk factors for developing cutaneous melanoma and criteria for identifying persons at risk: multicenter case-control study of the Central Malignant Melanoma Registry of the German Dermatological Society. J Invest Dermatol (1994) 1.31
Melanoma and use of sunscreens: an Eortc case-control study in Germany, Belgium and France. The EORTC Melanoma Cooperative Group. Int J Cancer (1995) 1.30
Cutaneous malignant melanoma and exposure to sunlamps or sunbeds: an EORTC multicenter case-control study in Belgium, France and Germany. EORTC Melanoma Cooperative Group. Int J Cancer (1994) 1.27
CD28-negative cytolytic effector T cells frequently express NK receptors and are present at variable proportions in circulating lymphocytes from healthy donors and melanoma patients. Eur J Immunol (1999) 1.26
Influence of sun exposures during childhood and during adulthood on melanoma risk. EPIMEL and EORTC Melanoma Cooperative Group. European Organisation for Research and Treatment of Cancer. Int J Cancer (1998) 1.26
Ex vivo IFN-gamma secretion by circulating CD8 T lymphocytes: implications of a novel approach for T cell monitoring in infectious and malignant diseases. J Immunol (2001) 1.24
Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery (1994) 1.23
Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNF alpha). Int J Cancer (1994) 1.22
Lipid composition of human malignant melanoma tumors at various levels of malignant growth. Eur J Biochem (1979) 1.21
Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol (1997) 1.20
Regulation of iron metabolism in the acute-phase response: interferon gamma and tumour necrosis factor alpha induce hypoferraemia, ferritin production and a decrease in circulating transferrin receptors in cancer patients. Eur J Clin Invest (1998) 1.19
First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma. Ann Oncol (2008) 1.18
Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst (1995) 1.15
Induction of the putative protective protein ferritin by infrared radiation: implications in skin repair. Int J Mol Med (2000) 1.15
Laparotomy enhances intraperitoneal tumor growth and abrogates the antitumor effects of interleukin-2 and lymphokine-activated killer cells. Surgery (1987) 1.15
A monoclonal antibody (LYP18) directed against the blood platelet glycoprotein IIb/IIIa complex inhibits human melanoma growth in vivo. Blood (1989) 1.14
Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer (2000) 1.14
IL-6 gene amplification and expression in human glioblastomas. Br J Cancer (2001) 1.14
Multicentre study of ultrasonographically guided axillary node biopsy in patients with breast cancer. Br J Surg (1999) 1.13
Differential regulation of breast tumor cell proliferation by stromal fibroblasts of various breast tissue sources. Int J Cancer (1996) 1.13
Clinical applications of TNF-alpha in cancer. Curr Opin Immunol (1998) 1.12
Chorioretinal vascular abnormalities associated with angioid streaks and pseudoxanthoma elasticum. Arch Ophthalmol (1998) 1.11
Distinct reactivity of Burkitt's lymphoma cell lines with eight monoclonal antibodies correlated with the ethnic origin. J Natl Cancer Inst (1984) 1.10
In vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytes. J Exp Med (1999) 1.08
Expansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptide. Clin Cancer Res (2001) 1.08
Chemotactic factor and P15E-related chemotaxis inhibitor in human melanoma cell lines with different macrophage content and tumorigenicity in nude mice. J Immunol (1987) 1.08
The case for sunscreens revisited. Arch Dermatol (1998) 1.07
Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib. Br J Cancer (2013) 1.06
Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats. Br J Cancer (1999) 1.06
Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours. Ann Oncol (1999) 1.04
TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects. Br J Cancer (2000) 1.04
The body site distribution of melanocytic naevi in 6-7 year old European children. Melanoma Res (2001) 1.04
Stromal influences on breast cancer cell growth. Br J Cancer (1992) 1.03
The activatory receptor 2B4 is expressed in vivo by human CD8+ effector alpha beta T cells. J Immunol (2001) 1.01
Low-dose tumor necrosis factor-alpha augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats. Int J Cancer (2000) 1.01
Infrequent expression of the MAGE gene family in uveal melanomas. Int J Cancer (1996) 1.01
Economical microscope configuration for direct mycological examination with fluorescence in dermatology. Dermatology (2000) 1.01
Human CD8(+) T cells expressing HLA-DR and CD28 show telomerase activity and are distinct from cytolytic effector T cells. Eur J Immunol (2001) 1.00
Synergistic antitumour effect of recombinant human tumour necrosis factor alpha with melphalan in isolated limb perfusion in the rat. Br J Surg (1996) 1.00
Frequent cytolytic T-cell responses to peptide MAGE-A10(254-262) in melanoma. Cancer Res (2001) 1.00
Evidence for alpha-melanocyte-stimulating hormone (alpha-MSH) receptors on human malignant melanoma cells. Int J Cancer (1988) 1.00
Diversity of the fine specificity displayed by HLA-A*0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide. J Immunol (1998) 0.99
Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study. Br J Cancer (1996) 0.99
Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities. Eur J Surg Oncol (2000) 0.99
VWF release and platelet aggregation in human melanoma after perfusion with TNF alpha. J Pathol (1995) 0.98
Variant translocation in a non endemic case of Burkitt's lymphoma: t (8;22) in an Epstein--Barr virus negative tumour and in a derived cell line. Eur J Cancer (1981) 0.98
Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues. Int Immunol (1999) 0.98
Mutation in the gene for connexin 30.3 in a family with erythrokeratodermia variabilis. Am J Hum Genet (2000) 0.97
The microscopic anatomy of experimental rat CC531 colon tumour metastases: consequences for immunotherapy? Clin Exp Metastasis (2000) 0.97
Hairy cell leukemia: functional, immunologic, kinetic, and ultrastructural characterization. Blood (1975) 0.97
Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma. Br J Cancer (1994) 0.96
Recombinant interleukin-2-based treatments for advanced melanoma: the experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. Cancer J Sci Am (1997) 0.96
Alteration of gangliosides in plasma and red cells of humans bearing melanoma tumors. Biochem Biophys Res Commun (1978) 0.96
Analysis of the cytolytic T lymphocyte response of melanoma patients to the naturally HLA-A*0201-associated tyrosinase peptide 368-376. Cancer Res (1999) 0.96
Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients. Cancer Res (1997) 0.96
Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions. Arch Surg (1995) 0.96
Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Dermatology (2005) 0.95
Ex vivo analysis of tumor antigen specific CD8+ T cell responses using MHC/peptide tetramers in cancer patients. Int Immunopharmacol (2001) 0.95
Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Français d'Immunothérape. J Clin Oncol (1999) 0.94